Free Oncology Symposia in Conjunction with 2024 ASCO Annual Meeting

MAY 31st In-Person Symposia
Includes Lunch & Beverage Selections
LUNCH SESSION: 11:00AM - 1:00PM CT

• Caring for Patients With Cancer in a Post-COVID World: Expert Guidance on the Latest Data and Therapeutic Advances to Mitigate Infection Risk

  Discussion Includes:
   

  • Clinical case discussions
  • Defining the risk of severe COVID-19 outcomes in patients with cancer
  • Next-generation mAbs for COVID-19 prevention
  • Integrating mAbs into management plans for patients with cancer
  • Audience question and answer session

  Faculty:
   

  • Cynthia Nguyen, PharmD, BCIDP
  • Mazyar Shadman, MD, MPH
  • Shmuel Shoham, MD

MAY 31st In-Person Symposia
Includes Dinner & Beverage Selections
DINNER SESSIONS: 6:30 PM - 8:30 PM CT

• Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer

  Discussion Includes:
   

  • Interactive Case Discussions I: Risk Assessment in HR-Positive/HER2-Negative Breast Cancer
  • Interactive Case Discussions II: Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative EBC in Your Practice
  • Interactive Case Discussions III: Individualizing Therapy for HR-Positive/HER2-Negative MBC in Your Practice
  • Interactive Case Discussions IV: Strategies for Promoting Adherence and Persistence to Oral Therapy in Your Practice

  Faculty:
   

  • Sara A. Hurvitz, MD, FACP
  • Erica L. Mayer, MD, MPH
  • Joyce O'Shaughnessy, MD

• Immunotherapy in HCC: Improving Outcomes Across the Disease Continuum

  Discussion Includes:
   

  • Immunotherapy-Based Combinations in Intermediate HCC (Eligible for TACE)
  • Immunotherapy-Based Combinations as Adjuvant Therapy for High-Risk HCC
  • Immunotherapy in Advanced/Metastatic HCC
  • Audience Question and Answer Session

  Faculty:
   

  • Richard S. Finn, MD
  • Sarah B. White, MD, MS, FSIR, FCIRSE
  • Mark Yarchoan, MD

• Myelofibrosis Expert Roundtable: State-of-the-Art Clinical Advances and Therapeutic Strategies From JAK Inhibition into the Future

  Discussion Includes:
   

  • State of the Union in Myelofibrosis Care
  • Selecting Initial Treatment for Patients With Myelofibrosis
  • Therapy in the Second Line and Beyond: Disease Progression or Intolerance to Initial Therapy
  • A Look to the Future: Novel Agents and Combination Therapy
  • Audience Question and Answer Session

JUN 1st In-Person Symposia
Includes Dinner & Beverage Selections
DINNER SESSIONS: 6:30 PM - 8:30 PM CT

• Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC

  Discussion Includes:
    

  • Latest Updates on (Neo)Adjuvant and 1L Systemic Therapy for Advanced/Metastatic NSCLC
  • Considerations for Advanced/Metastatic NSCLC With Central Nervous System Metastases EGFR TKI Mechanisms of Resistance
  • Highlights of Noteworthy ASCO 2024 Abstracts
  • Ongoing Studies and Investigational Therapies in EGFR-Mutated NSCLC
  • Closing Remarks and Question and Answer Session

  Faculty:
   

  • Nicolas Girard, MD, PhD
  • Natasha Leighl, MD, MMSC, FRCPC, FASCO
  • Karen L. Reckamp, MD, MS

• Targeted Therapies in Advanced Biliary Tract Cancer: Practical Strategies in a Changing Therapeutic Landscape

  Discussion Includes:
   

  • Selecting Initial Treatment for Patients With BTC
  • Targeting BTC Based on Genomic Alteration
  • A Look to the Future: Novel Agents and Targets
  • Highlight of Key ASCO 2024 Abstracts
  • Audience Question and Answer Session

  Faculty:
   

  • Mitesh J. Borad, MD
  • Shanu Modi, MD
  • Lipika Goyal, MD, MPhil

• Applying NCCN Guidelines for the Treatment of CLL/SLL in Clinical Practice: The Right Agent for the Right Patient at the Right Time

  Discussion Includes:
   

  • Importance of Individualizing CLL/SLL Therapy
  • Aligning Current Clinical Practice With NCCN CLL/SLL Guidelines
  • New and Emerging Treatments in Clinical Practice
  • Case-Based Panel Discussions
  • Spotlight of Key Abstracts at ASCO 2024
  • Final Thoughts and Audience Question and Answer Session

  Faculty:
   

  • Jeremy S. Abramson, MD, MMSc
  • Farrukh Awan, MD
  • Shuo Ma, MD, PhD

• Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

  Discussion Includes:
   

  • Steps Toward Precision Oncology: Attacking Endocrine Resistance in HR-Positive/HER2-Negative Breast Cancer
  • The Expanding Evidence Base for Oral SERDs and Other ER-Targeting Agents
  • A Peek at the Crystal Ball: Possibilities for the Future for HR-Positive/HER2-Negative Breast Cancer
  • Audience Question and Answer

  Faculty:
   

  • Aditya Bardia, MD, MPH, FASCO
  • Virginia Kaklamani, MD, DSc
  • Sarah Sammons, MD